Skip to main content
Bruno L. Cadilha on Muck Rack

Bruno L. Cadilha

Munich
As seen in: Nature, Science Magazine
Immuno-oncology, gene and cell therapy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Bruno L.

Contact Bruno L., search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy - British Journal of Cancer

|
By Theo Lorenzini, Bruno L. Cadilha, Florian Markl, Ruth Grünmeier, Matthias Seifert, Tobias Feuchtinger
| Nature Verified
Abstract Background In many situations, the therapeutic efficacy of CAR T cells is limited due to immune suppression and poor persistence. Immunostimulatory fusion protein (IFP) constructs have been advanced as a tool to convert suppressive signals into stimulation and thus promote the persistence of T cells, but no universal IFP design has been established so far. We now took advantage of a PD-1-CD28 IFP as a clinically relevant structure to define key determinants of IFP activity.
Open in Who Shared Issue with article?

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia - Nature Biotechnology

|
By Adrian Gottschlich, Moritz Thomas, Ruth Grünmeier, Daria Briukhovetska, Binje Vick, Florian Markl, Sophia Stock, Matthias Seifert, Bruno L. Cadilha, Christian Kellner, Eduardo Beltrán, Tobias Herold, Dominik Paquet, Louisa von Baumgarten, Carsten Marr, Stefanie Lesch, Veronika Igl, Sertac Dede, Thaddäus Strzalkowski, Theo Lorenzini, Franziska Modemann
| Nature Verified
Abstract Chimeric antigen receptor T cells (CAR-T cells) have emerged as a powerful treatment option for individuals with B cell malignancies but have yet to achieve success in treating acute myeloid leukemia (AML) due to a lack of safe targets.
Open in Who Shared Issue with article?

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors

|
By Bruno L. Cadilha, Mohamed-Reda Benmebarek, Klara Dorman, Arman Oner
| Science Magazine Verified
Abstract CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T cell suppression at the tumor site. T regulatory (Treg) cells suppress the immune response via inhibitory factors such as transforming growth factor–β (TGF-β). Treg cells expressing the C-C chemokine receptor 8 (CCR8) have been associated with poor prognosis in solid tumors.
Open in Who Shared Issue with article?
See all 4 articles